Boston Scientific: From Hypergrowth To Durable Compounding

Daniel James283 FollowersFollow5ShareSavePlay(8min)CommentsSummaryBoston Scientific has declined over 35% in six months, yet maintains double-digit growth and 28% operating margins, creating a compelling buy opportunity.BSX trades at mid-tier valuations, despite a 5-year revenue CAGR of 15.1% and EBITDA CAGR of 19%, outpacing Medtronic and Edwards Lifesciences.Growth drivers include electrophysiology, the WATCHMAN CHAMPION trial, and M&A, with the potential to expand the addressable market and sustain 11% EPS growth.Risks center on revenue/EPS deceleration and dependence on core products, while successful trials and M&A execution could catalyze significant upside. francisco jose sanchez/iStock via Getty Images Boston Scientific (BSX), maker of popular medical devices such as WATCHMAN, has been punished by the market over the last six months, with stock down more than 35%. This is partly due to rerating as growth is slowing from its peak andThis article was written byDaniel James283 FollowersFollowI am a part-time investor interested in equities, ETFs, macro, and emerging markets.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.